AKT1 and renal cell adenocarcinoma: Figure 2H shows that although each drug treatment separately significantly decreased Akt promoter activity compared with control cells, drug combinations decreased Akt promoter activity by 95%, suggesting that the additive effect of the combined drugs is sufficient to almost completely block the promoter activity of a major Pro‐survival kinase involved in RCC.